# Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects

> **NCT06363292** · PHASE1 · COMPLETED · sponsor: **Laboratorios Sophia S.A de C.V.** · enrollment: 37 (actual)

## Conditions studied

- Ophthalmological Agent Toxicity
- Bacterial Conjunctivitis

## Interventions

- **DRUG:** PRO-231
- **DRUG:** VIGAMOXI®

## Key facts

- **NCT ID:** NCT06363292
- **Lead sponsor:** Laboratorios Sophia S.A de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-30
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06363292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06363292, "Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06363292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*